UroGen Pharma (URGN) Prices 4.473M Share IPO at $13/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Wall Street indexes fall, with Iran and earnings season in focus
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
UroGen Pharma Announces Pricing of Initial Public Offering
May 3, 2017 5:56 PM EDTRAANANA, Israel, May 03, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today the pricing of its initial public offering of 4,473,373 ordinary shares at a public offering price of $13.00 per share for aggregate gross proceeds of approximately $58.2 million. The shares are scheduled to begin trading on The NASDAQ Global Market on May 4, 2017 under the ticker symbol URGN. In addition, UroGen Pharma granted the underwriters a 30-day option to purchase up to an additional 671,005 ordinary shares. The... More
